Physician profile
Kirk E Heyne
NPI 1346227816
$19,309.30
in general payments reported to CMS, 2019-2025
17 companies · $96.59 in 2025
The $96.59 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,645 · 2021: $2,832 · 2022: $185 · 2023: $168 · 2024: $282 · 2025: $96.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $16,414.16 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $1,550.00 | 2021 | |
| Eisai INC. | $496.73 | 2019-2025 | |
| Lilly USA, LLC | $181.07 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $159.45 | 2023-2025 | |
| Pfizer INC. | $139.52 | 2019 | |
| Merck Sharp & Dohme LLC | $115.13 | 2020-2024 | Keytruda, Zerbaxa, Dificid |
| Shionogi INC | $69.64 | 2019-2020 | |
| Biocompatibles, INC. | $49.49 | 2019 | |
| Genentech USA, INC. | $23.32 | 2024 | Tecentriq |
| Alexion Pharmaceuticals, INC. | $23.08 | 2022 | |
| Abbvie INC. | $22.36 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.34 | 2020 | |
| Melinta Therapeutics, LLC | $16.93 | 2024 | Rezzayo |
| Fujifilm Wako Diagnostics U.S.A. Corporation | $16.16 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Heyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.